Mezgebe Berhe

Mezgebe Berhe

Infectious Disease

9301 North Central Expressway
Suite 310
Dallas, TX 75231

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Journal: Annals of internal medicine

Published: December 22, 2025

Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV.

Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV.

Journal: Open forum infectious diseases

Published: October 28, 2025

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.

Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: June 04, 2025

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV.

Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV.

Journal: AIDS (London, England)

Published: April 07, 2025

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.

Journal: Medicine

Published: February 24, 2025

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.

Journal: HIV medicine

Published: December 20, 2024

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.

Journal: Open forum infectious diseases

Published: November 17, 2022

Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir.

Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir.

Journal: Proceedings (Baylor University. Medical Center)

Published: August 22, 2022

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.

Journal: The lancet. HIV

Published: May 31, 2022

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.

Journal: The New England journal of medicine

Published: May 11, 2022

Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.

Effectiveness of casirivimab/imdevimab in an intensive care unit patient with acute respiratory failure due to SARS-CoV-2 infection.

Journal: Proceedings (Baylor University. Medical Center)

Published: May 06, 2022

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.

Journal: The New England journal of medicine

Published: March 23, 2022

Showing 1-12 of 21

Last Updated: 09/26/2026